4yo0: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='4yo0' size='340' side='right'caption='[[4yo0]], [[Resolution|resolution]] 1.56Å' scene=''> | <StructureSection load='4yo0' size='340' side='right'caption='[[4yo0]], [[Resolution|resolution]] 1.56Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4yo0]] is a 6 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4yo0]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Rattus_norvegicus Rattus norvegicus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YO0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4YO0 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4yo0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yo0 OCA], [https://pdbe.org/4yo0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4yo0 RCSB], [https://www.ebi.ac.uk/pdbsum/4yo0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4yo0 ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/PDPN_HUMAN PDPN_HUMAN] | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 22: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Arimori | [[Category: Rattus norvegicus]] | ||
[[Category: Fujii | [[Category: Arimori T]] | ||
[[Category: Kitago | [[Category: Fujii Y]] | ||
[[Category: Takagi | [[Category: Kitago Y]] | ||
[[Category: Takagi J]] | |||
Revision as of 11:21, 3 May 2023
Crystal structure of monoclonal anti-human podoplanin antibody NZ-1 with bound PA peptideCrystal structure of monoclonal anti-human podoplanin antibody NZ-1 with bound PA peptide
Structural highlights
FunctionPublication Abstract from PubMedPlacement of a tag sequence is usually limited to either terminal of the target protein, reducing the potential of epitope tags for various labeling applications. The PA tag is a dodecapeptide (GVAMPGAEDDVV) that is recognized by a high-affinity antibody NZ-1. We determined the crystal structure of the PA tag/NZ-1 complex and found that NZ-1 recognized a central segment of the PA tag peptide in a tight beta-turn configuration, suggesting its compatibility with the insertion into a loop. This possibility was tested and confirmed using multiple integrin subunits and semaphorin. More specifically, the PA tag can be inserted at multiple locations within the alphaIIb subunit of the fibrinogen receptor alphaIIbbeta3 integrin without affecting the structural and functional integrity, while maintaining its high affinity toward NZ-1. The large choice of the sites for "epitope grafting" enabled the placement of the PA tag at a location whose accessibility is modulated during the biological action of the receptor. Thus, we succeeded in converting a general anti-tag antibody into a special reporter/activator anti-beta1 integrin antibody that can be classified as a ligand-induced binding site antibody. Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state.,Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J J Cell Sci. 2016 Feb 12. pii: jcs.176685. PMID:26872787[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||